Novartis Sees The Light And Plumps For Alcon Spin-Off

Having acquired Alcon for an eye-watering $52bn seven years ago, the Swiss major has decided that spinning off the eyecare business which has finally returned to growth (but is worth about half what Novartis paid in 2011) makes the most sense as it becomes a company even more focused on pharma.

Spinning top
SPIN-OFF PLANS SET OUT FOR ALCOM • Source: shutterstock.com

More from Business

More from Medtech Insight